For the 3rd year in a row, InSphero received the Supplier Performance Recognition Award from Scientist.com. Driven by real platform metrics across toxicology, pharmacology, and cell-based studies. A sign that advanced in vitro models are moving from evaluation to operation. Thank you!

MASH-TAG 2026 highlights now live! We are sharing new data on 3D liver spheroids for MASH drug discovery, Survodutide responses, and anti-fibrotic validation. More details on LinkedIn (post linked in the comments). 🎯 🧪

New blog alert! 🆕💡NIH has launched the Standardized Organoid Modeling (SOM) Institute, a key step for scaling organoid models and supporting regulatory use alongside the FDA Modernization Acts. With DOPPL SA, InSphero is expanding its platform to link organoids + 3D systems. Blog linked below🔗

Where the slopes meet the science ❄️🧪 Our Vice President of Liver Disease will share (virtually) how 3D human liver spheroids enable human-relevant in-vitro modeling for MASH drug discovery and anti-fibrotic validation at MASH-TAG 2026. Tune in: 4:40–5:00pm MST. Session highlights coming after!

Bridging science and strategy during Fierce JPM Week 🔬🤝 When? Jan 13–14, 2026 in San Francisco, CA! A focused forum at the intersection of science, capital, and policy, from AI-driven innovation to dealmaking and regulation. Send us a message if you are attending and would like to connect!

We are starting the year in San Francisco! 🌉 InSphero will be attending the 44th J.P. Morgan Annual Healthcare Meeting (Jan 12–15, 2026), with discussions spanning research, NAMs, and the practical use of 3D microtissue models. Interested in connecting there? Reach out to us to set up a meeting.

FDA Modernization Act 3.0 passed the U.S. Senate, bringing it closer to law and reinforcing a shift to modern, science-driven nonclinical testing. By removing outdated animal-testing language, it supports robust, human-relevant NAMs. We are excited to use this momentum at InSphero in the new year! 🚀

New year, new sphere 🌱 This year, our focus stays the same: advancing human-relevant science for better drug development decisions. Each year is a chance to sharpen our thinking, strengthen collaboration and keep improving together. Wishing you a healthy, successful and inspiring start to the year✨

👟✨ Screens off, endorphins on. We came together for the first-ever InSphero Silvesterlauf. Walking, a relaxed 2-3 km run, or running a 5 km push, moments like these remind us how important and energizing it can be to make an effort and head back to work with a clearer mind and a spring in our step.

🌟 Happy Holidays from InSphero! ☃️ Thank you to our colleagues, partners, and customers for the trust and collaboration that shaped our year. This period offers an opportunity to step back from the day-to-day and appreciate shared achievements. Wishing all joy and happiness! ✨ Drawn by Adrian Weber

Last week’s special at InSphero 🧀✨ Glühwein, great vibes, and even better company, followed by 20 raclettes, 2 bubbling fondue pots, and more cheese combinations than we could count. Finished with laughter and sweet conversations. We are so thankful to be a part of a creative and caring team!

Some years stand out through steady progress. Over the past year, we advanced with strong science, reliable execution, and trusted collaboration. As human-relevant in vitro approaches gain momentum, we’re proud to contribute. Thank you to everyone who made this year count! 💚

Wondering which InSphero plate fits your application?📊 Akura™ Ultra-Low Attachment and Gri3D® Hydrogel Plates support robust 3D cultures, but are optimized for different assay and data strategies. Our selection guide helps you choose the right platform. Still unsure? Learn more via the link below 🔗

Wonder why some drug candidates fail? 🔎💊 Danuglipron and Lotiglipron were both discontinued for different reasons. This highlights the importance of understanding drug safety. Human-relevant 3D liver models can help predict DILI risk and de-risk pipelines earlier. Use the link below for more info.

November at InSphero ✨ It was a month of science and growth: we welcomed Doppl SA, shared 3D in vitro research at ACT, MASOT, AASLD, and SDDN, launched our Bluesky account, and strengthened Swiss-EU research collaborations. Thank you for being part of it! Use the link below to stay up to date.

Happy International Mountain Day! 🗻✨ Mountains shape ecosystems, reveal layers shaped over millennia and inspire exploration. We see a similar depth in 3D cell culture, opening new horizons in understanding human biology. Their stories inspire our discoveries. Learn more with the link below. 🌄

New publication! Why does phenobarbital trigger liver tumors in rodents but not humans? Using our Human & Rat 3D InSight™ Liver Microtissues, Micromatrices uncovered shared receptor activation, but proliferation only in rats, revealing species-specific biomarkers. Read the publication series below.

One connected 3D ecosystem: standardized spheroids + self-organizing organoids. With Gri3D® joining the Akura™ Portfolio, we expand standardized 3D cell culture across tissues and disease models. Scalable, reproducible, and screening-ready. Learn more with the link below.

New blog!⚡️The FDA’s draft guidance to reduce non-human primates use signals a shift toward human-relevant in vitro systems. Our 3D InSight™ Liver Microtissues deliver early human insight, mechanistic clarity, and smarter cross-species decisions for evolving safety needs. Full blog linked below.

A full-day photoshoot gave us a fresh look at the people, tools, and workflows behind our 3D cell culture platforms. From lab moments to product shots, we captured the precision and passion driving our work. Here’s a peek behind the scenes, more to come soon. Learn more about us via the link below.

Curious how 3D MPS is reshaping human-relevant biology? Join our CSO Madhu Lal Nag this Wed, Dec 3 at 10am EST for a 3RsC webinar. Hear how next-gen MPS + organ-on-chip tech strengthen early tox decisions and support 3Rs with scalable, reproducible 3D in vitro models. Register with the link below.

A new preprint shows how Gri3D® microcavity plates enable scalable, reproducible neural organoids. Now part of our portfolio, through our recent acquisition, this technology brings the precision 3D biology needs for uniform tissues, reliable mapping, and smoother workflows.🔓Pre-print linked below.

The EMA backs NAMs, and we bring them to life. 🌍 Europe’s new Horizon Scanning Report shows rising support for human-relevant, 3Rs-aligned models. The message is clear: non-animal, predictive testing is becoming the standard. We’re ready to help unlock this shift with our reliable 3D systems.

New publication! USC researchers used our 3D InSight™ Human Liver Microtissues to study PFAS effects with single-cell sequencing. They found cell-type, donor, and sex-specific responses, plus disrupted lipid metabolism and immune signaling, advancing PFAS liver research. Publication linked below.

🚀 Taking 3D biology further! Gri3D® Hydrogel Microplates + InSphero = uniform organoids, clear imaging, automation-ready workflows & scalable assays. A unified 3D model ecosystem for faster, safer therapies. #3Dbiology #organoids #Gri3D #InSphero

Heading to A Coruña for SDDN 2025! Don’t miss the talk by our CEO Jan Lichtenberg: “Scaling Complexity in 3D Microtissue Platforms.” Join us on Nov 21st, from 11:00–13:00, for insights on 3D models, multi-omics data, and scalable NAMs. Let’s connect! More information linked in the comments.

It’s World Diabetes Day! 🩵🌎 At InSphero, our mission is to unlock the full potential of 3D in vitro technology. Today, we reaffirm our commitment to empowering researchers worldwide to reach their full potential and ultimately find a cure for diabetes. Learn more about our islet solutions below.

Proud to strengthen Swiss–EU innovation links! Great exchange in Bern with EU Commissioner Ekaterina Zaharieva on Swiss–EU innovation on advancing science through collaboration. Thanks to SERI, Innosuisse & the European Commission for an inspiring dialogue! Photo copyright “European Union, 2025”

🚀 Big news! InSphero has acquired DOPPL SA (including Sun Bioscience’s Gri3D® technology). By uniting spheroids and organoids, we’re setting a new standard in 3D biology. A stronger ecosystem. Connected innovation. A clearer route to better, safer therapies. 🌍Link to the full press release below.

Heading west for a deep dive into liver safety 🌄 Join us at ACT 2025 in Phoenix, AZ, Nov 16–19! See our posters on reproducible 3D liver models and DILI mechanisms on Monday, and our Exhibitor-Hosted Session on 3D InSight™ Liver Microtissues on Tuesday. More information linked below. See you there!

Our new webinar is out! Learn how InSphero’s 3D InSight™ Liver Microtissues advance human and animal hepatotoxicity studies, with insights from Bruno Filippi (InSphero) and Piyush Bajaj (Sanofi). Visit us at ACT 2025, booth #203, November 16th–19th in Phoenix, Arizona! Full webinar linked below 🔬

Tiny 3D livers tackling big safety questions! 🌱 Using InSphero’s 3D InSight™ Liver Microtissues, FDA researchers explored how 6PPD (a tire antioxidant) and 6PPD-Q impact the human liver, revealing how advanced in vitro models can better predict real-world effects! Publication linked in comments💡

ACT 2025 is almost here! ☀️🌵 We’re heading to Phoenix, AZ for the American College of Toxicology Annual Meeting (November 16th –19th). Visit us at booth #203, the poster session and exhibitor hosted session to explore how 3D human-relevant models are driving innovation in drug safety and discovery!

Hello Bluesky! 👋 We’re InSphero, pioneers in 3D-cell-based assays and organ-on-a-chip technology. Our mission: unlock the full potential of 3D in vitro and make drug discovery more human-relevant, efficient, and predictive. Excited to connect and share our journey!